The strength of TheraMe!’s team is its interdisciplinary expertise

Our team includes University Professors in Microfluidics and Bioinformatics, as well as experts in entrepreneurship, business administration, cancer biology and biomedical sciences.

  • Klaus Pflum is the managing director of TheraMe!. Over the past 35 years, he has held senior positions in major international banks and corporate finance houses. He acts as non-executive board member on several management boards. He holds an MBA from the University of Pforzheim, Germany and completed advanced studies in Oxford. He is a former Certified Public Accountant (CPA), Colorado, USA as well as a German Certified Tax Advisor (Steuerberater).

  • Prof. Christoph A. Merten is a professor for biomedical microfluidics at EPFL and holds an adjunct position at the Ludwig Institute for Cancer Research. In parallel, he has commercialized microfluidic technology and collaborated with big pharma. Christoph is the sole scientific founder of Velabs Therapeutics, now operating as Veraxa Biotech.

  • Hana Samet is an EPFL Alumni with entrepreneurial background in tech driven innovations. She has collaborated with successful startups in the medical device space. As a previous MedTech startup founder, she has hands-on experience of both product development and venture strategies.

  • Dr. Vida Vafaizadeh, has 20 years of research experience in tumor biomarkers, signal transduction, chemotherapy resistance and immuno-oncology. She has expertise in preclinical cancer research and is an experienced project manager.

  • Dr. Ngoc-Hien Du is a molecular biologist. She has been working on cellular genetics and transcriptomics explaining individual differences in circadian traits that are often disrupted in human diseases.

  • Vivien Streit is bringing over eight years of experience in medical devices and embedded systems. With a Master’s degree in Microengineering from EPFL, he has contributed in developing regulated software under ISO 13485 and IEC 62304, from prototypes to market-ready solutions.

  • As theraMe!’s Lab Manager, Stéphane responsible for setting up and running our lab. With deep NGS experience, he supports compliance, documentation, and translational workflows across biology and clinical teams.

  • Mehmet Sehir, a bioinformatician, specializes in NGS data analysis and variant calling pipeline development. He holds an MSc in Bioinformatics and Data Analysis from the University of Geneva and gained significant experience at HUG, developing pipelines and working on data analysis and visualization with Python and R.

  • Aa R&D Engineer, Francesca contributes to the testing and optimization of our microfluidic systems and workflows for high-throughput drug testing. With a background in biomedical engineering and organ-on-chip technology, she bridges bioengineering and translational research to advance personalized therapy solutions.

Scientific Advisors

  • Prof. Federica Eduati is an Assistant Professor of Systems Biology for Oncology at Eindhoven University of Technology in the Netherlands. She is an expert in personalized cancer therapies. Her approach combines both data science and experimental methods.

  • Dr. med. Michael Quante is GI fellow and principle investigator at the University hospital of Freiburg. His lab is focusing on a translational research approach on Barrett's Esophagus and esophageal adenocarcinoma. He is working to facilitate the clinical realization of basic science principles in order to improve the care and treatment of esophagus cancer patients and the surveillance of patients with Barrett's Esophagus.

  • Dr. Delamarche is an independent consultant, Licensing Manager at Knowledge Transfer Unil CHUV, and Lecturer at ETH Zurich. Through his 31 years in the industry (IBM Research Zurich, start-ups), Dr. Delamarche made pioneering contributions to the field of microfluidics and worked on many bioanalytical, medtech, and in vitro diagnostic projects. He is passionate about applied research and a contributor to scientific panels for governmental agencies and large research institutions.

Consultants

  • Dr. Bence Szalai is bioinformatics consultant at TheraMe!. He develops the workflows to analyse the data coming from TheraMe! screens. Previously, during his post-doc fellowships he worked extensively with cancer gene expression and drug sensitivity data.

Who are we?

TheraMe! a medtech spinoff from EPFL is at the forefront of advancing cancer treatment. TheraMe! AG was founded in 2023 with a successful seed round. Our journey is rooted in over a decade of academic research conducted in collaboration with a multinational consortium. This solid foundation drives our commitment to revolutionize cancer therapy through state-of-the-art microfluidic technology.

Internationally renowned experts and university professors in the fields of microfluidics, bioinformatics and clinical oncology work together at TheraMe!, having a single goal in mind: Identifying the very best treatment option for any cancer patient, at any stage of the disease!

Our mission to redefine cancer care. At TheraMe!, we're not just advancing medicine, we're transforming lives.

Are you ready to make a difference in the world and become part of our patient-centered team that is focused on making personalized cancer therapy possible?